Novel biomarkers for prostate cancer (PCa) are currently being assessed for utility in PCa
diagnosis. This article aims to provide concise information on the current findings that impact …

Prostate cancer (PCa), a highly heterogeneous disease, is the one of the leading cause of
morbidity and mortality in the developed countries. Historically used biomarkers such as …

The aim of this review is to critically analyze the current state of research in selected
biomarkers and genomic-based tests for prostate cancer (PCa) diagnosis, staging …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Along with significant advances in prostate cancer biology research, we also observe the
rapid development of modern diagnostic tests. New biomarkers are derived to detect …

Prostate cancer (PCa) is the most commonly diagnosed male cancer in the United States.
The prostate-specific antigen (PSA) biomarker has been widely used to screen men for …

Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of
cancer-related death. Early detection of prostate cancer is largely determined by a widely …

Although prostate-specific antigen (PSA) remains the most used test to detect prostate
cancer (PCa), the limited specificity and an elevated rate of overdiagnosis are the main …

Objective: In recent years, several biomarkers alternative to standard prostate specific
antigen (PSA) for prostate cancer (PCa) diagnosis have become available. The aim of this …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …